• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study: Long-term use of inhaled corticosteroids may heighten risk of bone fractures in COPD patients

February 6, 2018 By Sarah Faulkner

asthma inhalerResearchers reported this month that in men and women with chronic obstructive pulmonary disease, long-term use of inhaled corticosteroids may be linked to an increased risk of bone fractures.

Previous research has shown that the inhaled drugs, used to treat COPD, impact bone mineral density based on the dose of the corticosteroid, especially in post-menopausal women.

Investigators from McGill University and the Jewish General Hospital-Lady Davis Research Institute studied data from COPD patients ages 55 and older. The researchers used data from the Quebec healthcare databases, following a cohort of patients from 1990 until 2007. They specifically looked for cases of hip and upper extremity fractures, while controlling for age, sex and follow-up time.

The researchers reported that in the 240,000-patient cohort, 19,396 people experienced a fracture during a mean of 5.3 years. But the team noted that they observed a statistically significant jump in the fracture rate for people who used inhaled corticosteroids for more than four years at a dose of at least 1,000 mcg or more per day.

“Since fractures are more frequent in women than men, our study suggests that the excess number of fractures associated with ICS will be greater in women even though we did not find that the risk increase was particularly higher in women than in men,” lead researcher Samy Suissa said in prepared remarks. “Quantifying this excess number would require a larger cohort.”

The study, which was partially funded by Novartis (NYSE:NVS), had a few limitations due to the database upon which it was based. The database didn’t include information on the patients’ smoking habits, body mass index or pulmonary function – all of which could impact someone’s risk of a bone fracture.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Orthopedics, Pharmaceuticals, Research & Development Tagged With: Novartis

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS